SPY382.47+1.05 0.28%
DIA313.51+0.52 0.17%
IXIC13,007.62+9.87 0.08%

Insider Trends: Insider at Vertex Pharmaceuticals Receives Stock Award Uses Portion to Pay Taxes, Scaling Down 90-Day Buy Trend

· 02/05/2021 12:01

04:54 PM EST, 02/05/2021 (MT Newswires) -- Dr Jeffrey M Leiden, Director and Executive Chairman, awarded 83,888 shares in Vertex Pharmaceuticals (VRTX) and sold 8,599 shares concurrently to meet tax obligations on Feb 03, 2021. After accounting for tax obligations this transaction resulted in a net acquisition of 75,289 company shares. Dr Leiden has control over 78,040 shares of the company of which 77,600 shares are controlled directly and 440 shares indirectly following the transactions outlined in the Form 4 SEC filing. These holdings have an approximate market value of $16.7 million as of the prior-day closing price.

During the most recent 90-day period, previous to the date of this filing, there have been 11 insider transactions reported to the SEC for Vertex Pharmaceuticals. These transactions came from the activities of 7 separate insiders that resulted in a net acquisition of 148,939 company shares. Relative to the preceding 90-day window of time, there were 7 transactions from 3 insiders that resulted in the net disposition of 1,787 shares.

This level of transactions is below that of the peer group average in the 324-company Bio Therapeutic Drugs peer group over the last 90-day period. Peer group activity averaged 56.3 transactions per company, with company insiders acquiring on average 24,488 shares.

SEC Story Link http://www.sec.gov/Archives/edgar/data/875320/000120919121008126/xslF345X03/doc4.xml

[Disclaimer]
This report does not constitute a recommendation to purchase or sell any security and the analysts are not registered investment advisors. Further analysis is recommended before undertaking any position in any security. Any risks are solely the responsibility of the buyer/seller. The authors, publishers and distributors of the MT Newswires Live Briefs service and any associates thereof accept no liability for the content or actions taken by anyone or institution utilizing this report.